Opportunities to Improve Glaucoma Treatment

December 14, 2017

 

The goal of most glaucoma treatments is to lower eye pressure more effectively or more safely for longer periods of time.

A new molecular class of drugs, rho kinase (ROCK) inhibitors, is in development for the treatment of glaucoma patients. With minimal systemic side effects and tolerable ocular side effects, ROCK inhibitors have no contraindications - thus offering doctors and patients a necessary treatment option with convenient, once-a-day dosing.

Learn more about how this class fits into the timeline of advances in glaucoma treatment, and the potential that ROCK inhibitors may hold.

Read the Whitepaper now